Methods of treating ulcerative colitis with chimeric anti-TNF antibodies
AssigneesNew York University, Centocor, Inc.
InventorsJunming Le, Jan Vilcek, Peter Daddona, John Ghraveb, David Knight, Scott Siegel
Life of this patent
Estimating the term…
Abstract
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Claims26
A method of treating ulcerative colitis in a human in need thereof, comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody for a sufficient period of time to treat the ulcerative colitis, wherein said anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2.
A method of treating ulcerative colitis in a human in need thereof, comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody cA2, or a TNF binding fragment thereof, for a sufficient period of time to treat the ulcerative colitis.
A method of treating ulcerative colitis in a human in need thereof, comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody for a sufficient period of time to treat the ulcerative colitis, wherein said anti-TNF chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO:
- 5.
A method of treating ulcerative colitis in a human in need thereof, comprising administering to the human a single or divided 0.1-50 mg/kg dose of an anti-TNF chimeric antibody for a sufficient period of time to treat the ulcerative colitis, wherein said anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2.
A method of treating ulcerative colitis in a human in need thereof, comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody for a sufficient period of time to treat the ulcerative colitis, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of TNF to monoclonal antibody cA2.
A method of treating ulcerative colitis in a human in need thereof, comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody for a sufficient period of time to treat the ulcerative colitis, wherein said anti-TNF chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO:
- 5 and an IgG1 human constant region.
Dependencies are inferred from the claim text.